Download presentation
Presentation is loading. Please wait.
Published byCorey Stephens Modified over 6 years ago
1
Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease Baolei Guo, MD, Qiwen Tan, MSc, Daqiao Guo, MD, Zhenyu Shi, MD, Chunyan Zhang, MSc, Wei Guo, MSc Journal of Vascular Surgery Volume 60, Issue 4, Pages (October 2014) DOI: /j.jvs Copyright © Terms and Conditions
2
Fig 1 Box and whisker plot shows the clopidogrel response in the enrolled patients, as assessed by platelet mapping assay in response to 20 μmol/L of adenosine diphosphate (ADP) after a stable administration of clopidogrel. The horizontal line within each box represents the median, and the lower and upper borders of each box represent the 25th and the 75th percentiles, respectively, and the whiskers mark the 95% confidence intervals. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © Terms and Conditions
3
Fig 2 Kaplan-Meier curve shows primary vessel patency during follow-up in patients with and without the cytochrome P450 (CYP) 2C19 loss-of-function (LOF) allele (n = 50). P = .006 by log-rank test. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © Terms and Conditions
4
Fig 3 Estimated rates of primary end points are shown according to platelet reactivity characteristics (n = 50). P = .012 by log-rank test. HPR, High platelet reactivity; NPR, normal platelet reactivity. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.